Fig. 2

MCL-1 antagonism induced cell death in MDA-MB-468-2A cells but not MDA-MB-231-2A cells grown as monolayers on plastic. Representative western blots of BIM, MCL-1, BCL-2, BCL-XL and Cleaved Caspase 3 (CC3) in (a) MDA-MB-468-2A and (b) MDA-MB-231-2A cells at 0, 12, 24, 36 and 48 hours after treatment with DOX or vehicle. Representative western blots showing the levels of BIM, MCL-1, BCL-2, and BCL-XL following immunoprecipitation with antibodies to MCL-1, BCL-2 and BCL-XL in (c) MDA-MB-468-2A and (d) MDA-MB-231-2A cells 24 hours after treatment with DOX or vehicle. Bar graphs depicting the average fraction of apoptotic cells (Annexin V-positive) in (e) MDA-MB-468-2A or empty vector (EV) and (f) MDA-MB-231-2A or EV cells treated with DOX or vehicle at 24 and 48 hours. (g) Bar graphs depicting the average fraction of apoptotic cells in MDA-MB-468-2A or MDA-MB-468-EV and (h) MDA-MB-231-2A or MDA-MB-231-EV cells treated with DOX or vehicle and treated with ABT-263 or vehicle at 24 hours. All graphs and western blots are the average of three independent experiments. Bars indicate significantly significant groups, p value paired t tests. DOX doxycycline, MCL-1 myeloid cell leukemia 1 (Color figure online)